Enovis (NYSE:ENOV) Trading Down 7.1% – What’s Next?

Shares of Enovis Corporation (NYSE:ENOV) traded down 7.1% during trading on Wednesday . The company traded as low as $23.67 and last traded at $23.70. Approximately 441,065 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 1,084,874 shares. The stock had previously closed at $25.52.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company reduced their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Evercore set a $32.00 price target on shares of Enovis in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research report on Wednesday. William Blair started coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.71.

Enovis Price Performance

The business’s fifty day moving average price is $23.34 and its 200 day moving average price is $23.79. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The stock has a market cap of $1.46 billion, a P/E ratio of -1.28 and a beta of 1.39.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts forecast that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 4,200 shares of company stock worth $92,084 over the last quarter. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after acquiring an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of Enovis during the third quarter worth about $83,435,000. Paradigm Capital Management Inc. NY grew its holdings in shares of Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. River Road Asset Management LLC increased its stake in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after buying an additional 46,289 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after buying an additional 287,687 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.